EffRx Pharmaceuticals: Osteoporosis Patients in Southeast Asia Get Access to Binosto®

EffRx launches Binosto® – buffered soluble alendronate – in Malaysia and Singapore

FREIENBACH, Switzerland–(BUSINESS WIRE)–EffRx Pharmaceuticals SA today announced that physicians in Malaysia and Singapore treating patients with postmenopausal osteoporosis have a new therapeutic option: buffered soluble alendronate (Binosto®). This novel therapeutic option, which is already available in fifteen countries worldwide, provides gold-standard fracture risk reduction and offers better upper gastrointestinal safety profile than reported for alendronate tablets.1-3

go to the full article on BUSINESS WIRE